文献速递胸部肿瘤

培美曲塞、贝伐珠单抗或联合方案用于晚期非鳞非小细胞肺癌维持治疗:ECOG-ACRIN 5508

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508.
PubMed 文献 · J Clin Oncol · 2019-07-30

本研究为随机对照试验,纳入晚期非鳞非小细胞肺癌患者,诱导治疗后随机接受贝伐珠单抗、培美曲塞或两药联合维持治疗。主要终点总生存期无显著差异,联合组无生存获益且毒性更高,因此不推荐联合维持。

要点

  • 培美曲塞单药与贝伐珠单抗单药维持治疗的总生存期无显著差异。
  • 联合维持治疗未改善总生存,且3-4级毒性发生率更高。
  • 不推荐贝伐珠单抗联合培美曲塞用于维持治疗。

核心结论

  • 贝伐珠单抗或培美曲塞单药维持治疗对晚期非鳞非小细胞肺癌有效。
  • 贝伐珠单抗联合培美曲塞维持治疗无生存获益且毒性更高,不推荐使用。

研究设计与样本

  • 随机对照研究,纳入1516例晚期非鳞非小细胞肺癌患者,经卡铂+紫杉醇+贝伐珠单抗诱导后无进展者874例随机分组。

主要发现

  • 3-4级毒性发生率在贝伐珠单抗组、培美曲塞组和联合组分别为29%、37%和51%。

临床怎么用

  • 对于晚期非鳞非小细胞肺癌,诱导治疗后无进展者可选择贝伐珠单抗或培美曲塞单药维持治疗。
  • 避免使用贝伐珠单抗联合培美曲塞作为维持治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non-small-cell lung cancer (NSCLC). The combination of bevacizumab and pemetrexed has also demonstrated efficacy. We conducted a randomized study to determine the optimal maintenance therapy. PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC and no prior systemic therapy received carboplatin (area under the curve, 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) for up to four cycles. Patients without progression after four cycles were randomly assigned to maintenance therapy with bevacizumab (15 mg/kg), pemetrexed (500 mg/m2), or a combination of the two agents. The primary end point was overall survival, with bevacizumab serving as the control group. RESULTS: Of the 1,516 patients enrolled, 874 (57%) were randomly assigned after induction therapy to one of the three maintenance therapy groups. With a median follow-up of 50.6 months, median survival with pemetrexed was 15.9 months, compared with 14.4 months with bevacizumab (hazard ratio [HR], 0.86; P = .12); median survival with pemetrexed and bevacizumab was 16.4 months (HR, 0.9; P = .28); median progression-free survival was 4.2, 5.1 (HR, 0.85; P = .06), and 7.5 months (HR, 0.67; P < .001) for the three groups, respectively. Incidence of worst grade 3 to 4 toxicity was 29%, 37%, and 51%, respectively, for bevacizumab, pemetrexed, and the combination regimen. CONCLUSION: Single-agent bevacizumab or pemetrexed is efficacious as maintenance therapy for advanced nonsquamous NSCLC. Because of a lack of survival benefit and higher toxicity, the combination of bevacizumab and pemetrexed cannot be recommended.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramalingam SS, Dahlberg SE, Belani CP, et al. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019. PMID: 31361535. doi:10.1200/JCO.19.01006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。